← Back to headlines
Eli Lilly to Acquire Cancer Biotech Kelonia for Up to $7 Billion
Eli Lilly has agreed to acquire the cancer biotechnology company Kelonia in a deal valued at up to $7 billion. This acquisition aims to expand Lilly's portfolio in cancer drug development.
20 Apr, 13:02 — 20 Apr, 13:07
The Story
Analyzing sources…
Source Diversity
Source Diversity
Moderate (27/100)2 sources— more sources would strengthen this score15/33
Spectrum spread— 2/5 buckets covered8/33
Far L
Left1
Left (1)
cnbc
Center1
Center (1)
bloomberg
Right
Far R
Geographic diversity— 1 region4/34
US2
ℹAll sources from US region
ℹOnly 2 sources cover this story
Sources
Showing 2 of 2 sources
bloombergHigh22h ago
Lilly to Buy Cancer Biotech Kelonia for Up to $7 Billion - Bloomberg.com
Lilly to Buy Cancer Biotech Kelonia for Up to $7 Billion Bloomberg.com
Read full article →cnbcMostly Factual22h ago
Eli Lilly agrees to acquire cancer drug maker Kelonia in deal worth up to $7 billion
Kelonia is developing technology to reprogram patients' T-cells inside the body so those cells can attack cancer, called in vivo CAR-T.
Read full article →Coverage Timeline
First report: cnbc · 20 Apr, 13:02|Full coverage: 2 · 6m|Window: 6m
Left-leaningCenterRight-leaning
